Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ernexa TherapeuticsERNA +4.92%30 EV-to-FCF is 0.56 as of Jul. 27, 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 343 Biotechnology companies, Ernexa Therapeutics ranks better than 81.92% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ernexa Therapeutics's Enterprise Value is $-4.06 Mil.
Ernexa Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.22 Mil. Therefore, Ernexa Therapeutics's EV-to-FCF for today is 0.56.
The historical rank and industry rank for Ernexa Therapeutics's EV-to-FCF or its related term are showing as below:
ERNA'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.44 Med: -1 Max: 0.59
Current: 0.56
During the past 6 years, the highest EV-to-FCF of Ernexa Therapeutics was 0.59. The lowest was -3.44. And the median was -1.00.
ERNA's EV-to-FCF is ranked better than 81.92% of 343
companies
in the Biotechnology industry
Industry Median: 14.79
vs ERNA: 0.56
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ernexa Therapeutics's PE Ratio (TTM) for today is calculated as:
Ernexa Therapeutics's share price for today is $4.05.
Ernexa Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ernexa Therapeutics EV-to-FCF Related Terms
Ernexa Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ernexa Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ernexa Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ernexa Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ernexa Therapeutics's EV-to-FCF falls into.
Ernexa Therapeutics's current Enterprise Value is $-4.06 Mil.
Ernexa Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ernexa Therapeutics (ERNA) has a EV-to-FCF of 0.56 as of Jul. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ernexa Therapeutics and its competitors. According to the industry distribution chart, Ernexa Therapeutics ranks #62 out of 343 companies in the Biotechnology industry, placing it in the top 18.1%.
Is Ernexa Therapeutics' EV-to-FCF too high?
Ernexa Therapeutics' current EV-to-FCF is 0.56. The Biotechnology industry median EV-to-FCF is 14.79. Ernexa Therapeutics' value of 0.56 is 96.2% below this industry median. Based on the distribution chart, Ernexa Therapeutics ranks #62 out of 343 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' EV-to-FCF compare to CDIO and LABT?
According to the Biotechnology industry distribution chart, Ernexa Therapeutics ranks #62 out of 343 companies for EV-to-FCF. This places Ernexa Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 14.79. Ernexa Therapeutics' value of 0.56 is 96.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.79, based on 343 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ernexa Therapeutics's current EV-to-FCF of 0.56 is 96.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ernexa Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ernexa Therapeutics's current EV-to-FCF is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current EV-to-FCF of 0.56. The current EV-to-FCF is 0.56 and 96.2% below the Biotechnology industry median of 14.79. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current EV-to-FCF is 0.56 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score
Get the complete analysis for ERNA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERNA has been successfully added to your 
